Determinants for achieving the LDL-C target of lipid control for secondary prevention of cardiovascular events in Taiwan

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  Ho, Li Ting ^a   Yin, Wei Hsian ^b   Chuang, Shao Yuan ^c   Tseng, Wei Kung ^d   Wu, Yen Wen ^e   Hsieh, I Chang ^f   Lin, Tsung Hsien ^g   Li, Yi Heng ^h   Huang, Lien Chi ⁱ   Wang, Kuo Yang ^j   Ueng, Kwo Chang ^j   Fang, Ching Chang ^k   Pan, Wen Harn ^c   Yeh, Hung I ^l   Wu, Chau Chung ^a,m   Chen, Jaw Wen ^b  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^d I SHOU UNIVERSITY   (Taiwan)

^e FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

^f CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^g KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^h NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

ⁱ TAIPEI HOSPITAL   (Taiwan)

^j CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^k TAINAN MUNICIPAL HOSPITAL   (Taiwan)

^l MACKAY MEMORIAL HOSPITAL   (Taiwan)

^m NATIONAL TAIWAN UNIVERSITY   (Taiwan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; CHOLESTEROL; COLESTYRAMINE; CREATINE KINASE; EZETIMIBE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIVER ENZYME; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; AGING; ARTICLE; BODY HEIGHT; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CREATINE KINASE BLOOD LEVEL; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DYSLIPIDEMIA; FEMALE; FOLLOW UP; HUMAN; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; OBSERVATIONAL STUDY; PHYSICAL ACTIVITY; PRACTICE GUIDELINE; PROSPECTIVE STUDY; SECONDARY PREVENTION; SEX DIFFERENCE; SMOKING CESSATION; TAIWAN; TRIACYLGLYCEROL BLOOD LEVEL; VITAL SIGN; BLOOD; COMPLICATION; HYPERCHOLESTEROLEMIA; MIDDLE AGED; TREATMENT OUTCOME;

AGED; CHOLESTEROL, LDL; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SECONDARY PREVENTION; TAIWAN; TREATMENT OUTCOME;

EID: 84959306091     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0116513     Document Type: Article

References (37)

1. Laslett LJ, Alagona P Jr., Clark BA 3rd, Drozda JP Jr., Saldivar F, et al. (2012) The worldwide environment of cardiovascular disease: prevalence, diagnosis, therapy, and policy issues: a report from the American College of Cardiology. J Am Coll Cardiol 60: S1-49. doi: 10.1016/j.jacc.2012.11.002 PMID: 23257320
2. Verschuren WM, Jacobs DR, Bloemberg BP, Kromhout D, Menotti A, et al. (1995) Serum total cholesterol and long-term coronary heart disease mortality in different cultures. Twenty-five-year follow-up of the seven countries study. JAMA 274: 131-136. PMID: 7596000
3. Martin MJ, Hulley SB, Browner WS, Kuller LH, Wentworth D (1986) Serum cholesterol, blood pressure, and mortality: implications from a cohort of 361,662 men. Lancet 2: 933-936. PMID: 2877128
4. (1988) Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel. Arch Intern Med 148: 36-69. PMID: 3422148
5. (1993) Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 269: 3015-3023. PMID: 8501844
6. LaRosa JC, Hunninghake D, Bush D, Criqui MH, Getz GS, et al. (1990) The cholesterol facts. A summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease. A joint statement by the American Heart Association and the National Heart, Lung, and Blood Institute. The Task Force on Cholesterol Issues, American Heart Association. Circulation 81: 1721-1733. PMID: 2184951
7. National Cholesterol Education Program Expert Panel on Detection E, Treatment of High Blood Cholesterol in A (2002) Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106: 3143-3421. PMID: 12485966
8. Smith SC Jr., Allen J, Blair SN, Bonow RO, Brass LM, et al. (2006) AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 113: 2363-2372. PMID: 16702489
9. Pearson TA, Laurora I, Chu H, Kafonek S (2000) The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 160: 459-467. PMID: 10695686
10. Primatesta P, Poulter NR (2000) Lipid concentrations and the use of lipid lowering drugs: evidence from a national cross sectional survey. BMJ 321: 1322-1325. PMID: 11090516
11. Kim HS, Wu Y, Lin SJ, Deerochanawong C, Zambahari R, et al. (2008) Current status of cholesterol goal attainment after statin therapy among patients with hypercholesterolemia in Asian countries and region: the Return on Expenditure Achieved for Lipid Therapy in Asia (REALITY-Asia) study. Curr Med Res Opin 24: 1951-1963. doi: 10.1185/03007990802138731 PMID: 18547466
12. Yin W-H, Wu C-C, Chen J-W (2012) Registry of Lipid Control and the Use of Lipid-lowering Drugs for Secondary Prevention of Cardiovascular Events in Patients with Established Atherosclerotic Disease in Taiwan: Rationality and Methods. International Journal of Gerontology 6: 241-246.
13. Jeng JS, Yin WH, Huang CC, Chuang SY, Yeh HI, et al. (2013) Guideline-adherent therapy in patients with cardiovascular diseases in Taiwan. J Formos Med Assoc. doi: 10.1016/j.jfma.2013.10.007 PMID: 24275017
14. Maron DJ, Fazio S, Linton MF (2000) Current perspectives on statins. Circulation 101: 207-213. PMID: 10637210
15. Kotseva K, Wood D, De Backer G, De Bacquer D, Pyorala K, et al. (2009) Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet 373: 929-940. doi: 10.1016/S0140-6736(09)60330-5 PMID: 19286092
16. Cooney MT, Storey S, Taylor L, Dudina A, Hall M, et al. (2009) EUROASPIRE (European Action on Secondary Prevention through Intervention to Reduce Events) III - a comparison of Irish and European results. Ir Med J 102: 113-116. PMID: 19552291
17. Group EIS (2001) Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 22: 554-572. PMID: 11259143
18. Kotseva K, Wood D, De Backer G, De Bacquer D, Pyorala K, et al. (2009) EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil 16: 121-137. doi: 10.1097/HJR.0b013e3283294b1d PMID: 19287307
19. Jones PH, Nair R, Thakker KM (2012) Prevalence of dyslipidemia and lipid goal attainment in statintreated subjects from 3 data sources: a retrospective analysis. J Am Heart Assoc 1: e001800. doi: 10.1161/JAHA.112.001800 PMID: 23316314
20. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, et al. (2002) Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360: 1623-1630. PMID: 12457784
21. Deedwania P, Stone PH, Bairey Merz CN, Cosin-Aguilar J, Koylan N, et al. (2007) Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: results of the Study Assessing Goals in the Elderly (SAGE). Circulation 115: 700-707. PMID: 17283260
22. Heart Protection Study Collaborative G (2002) MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360: 7-22. PMID: 12114036
23. Ko DT, Mamdani M, Alter DA (2004) Lipid-lowering therapy with statins in high-risk elderly patients: the treatment-risk paradox. JAMA 291: 1864-1870. PMID: 15100205
24. Reibis RK, Bestehorn K, Pittrow D, Jannowitz C, Wegscheider K, et al. (2009) Elevated risk profile of women in secondary prevention of coronary artery disease: a 6-year survey of 117,913 patients. J Womens Health (Larchmt) 18: 1123-1131. doi: 10.1089/jwh.2008.1082 PMID: 19630543
25. Singh M, Chin SH, Crothers D, Giles P, Al-Allaf K, et al. (2013) Time Trends of Gender-Based Differences in Lipid Goal Attainments During Secondary Prevention of Coronary Artery Disease: Results of a 5-Year Survey. Am J Ther.
26. Anderson RD, Pepine CJ (2007) Gender differences in the treatment for acute myocardial infarction: bias or biology? Circulation 115: 823-826. PMID: 17309930
27. Radovanovic D, Erne P, Urban P, Bertel O, Rickli H, et al. (2007) Gender differences in management and outcomes in patients with acute coronary syndromes: results on 20,290 patients from the AMIS Plus Registry. Heart 93: 1369-1375. PMID: 17933995
28. Mendis S, Abegunde D, Yusuf S, Ebrahim S, Shaper G, et al. (2005) WHO study on Prevention of REcurrences of Myocardial Infarction and StrokE (WHO-PREMISE). Bull World Health Organ 83: 820-829. PMID: 16302038
29. Saposnik G, Goodman SG, Leiter LA, Yan RT, Fitchett DH, et al. (2009) Applying the evidence: do patients with stroke, coronary artery disease, or both achieve similar treatment goals? Stroke 40: 1417-1424. doi: 10.1161/STROKEAHA.108.533018 PMID: 19213947
30. Heeley E, Anderson C, Patel A, Cass A, Peiris D, et al. (2012) Disparities between prescribing of secondary prevention therapies for stroke and coronary artery disease in general practice. Int J Stroke 7: 649-654. doi: 10.1111/j.1747-4949.2011.00613.x PMID: 21978147
31. Furie KL, Kasner SE, Adams RJ, Albers GW, Bush RL, et al. (2011) Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the american heart association/american stroke association. Stroke 42: 227-276. doi: 10.1161/STR. 0b013e3181f7d043 PMID: 20966421
32. Chandratheva A, Lasserson DS, Geraghty OC, Rothwell PM, Oxford Vascular S (2010) Populationbased study of behavior immediately after transient ischemic attack and minor stroke in 1000 consecutive patients: lessons for public education. Stroke 41: 1108-1114. doi: 10.1161/STROKEAHA.109. 576611 PMID: 20395614
33. Selim MH, Molina CA (2012) High-dose statin for every stroke: the good, the bad, and the unknown. Stroke 43: 1996-1997. doi: 10.1161/STROKEAHA.111.648832 PMID: 22569937
34. Ruckert IM, Schunk M, Holle R, Schipf S, Volzke H, et al. (2012) Blood pressure and lipid management fall far short in persons with type 2 diabetes: results from the DIAB-CORE Consortium including six German population-based studies. Cardiovasc Diabetol 11: 50. PMID: 22569118
35. Jaussi A, Noll G, Meier B, Darioli R (2010) Current cardiovascular risk management patterns with special focus on lipid lowering in daily practice in Switzerland. Eur J Cardiovasc Prev Rehabil 17: 363-372. doi: 10.1097/HJR.0b013e328333c1d9 PMID: 20168234
36. Zhao S, Wang Y, Mu Y, Yu B, Ye P, et al. (2014) Prevalence of dyslipidaemia in patients treated with lipid-lowering agents in China: results of the DYSlipidemia International Study (DYSIS). Atherosclerosis 235: 463-469. doi: 10.1016/j.atherosclerosis.2014.05.916 PMID: 24950001
37. Kuznik A, Mardekian J (2011) Trends in utilization of lipid- and blood pressure-lowering agents and goal attainment among the U.S. diabetic population, 1999-2008. Cardiovasc Diabetol 10: 31. doi: 10.1186/1475-2840-10-31 PMID: 21496321